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Abstract
Background: Cancer is a major cause of morbidity, disability, and mortality worldwide, and breast cancer is the most common
cause of death in women. Different modalities of cancer treatment can have adverse effects that reduce the quality of life of
patients and lead to treatment interruptions, if not managed properly. The use of mobile technologies has brought innovative
possibilities for improving health care. Mobile apps can help individuals manage their own health and well-being and may also
promote healthy lifestyles and information access.
Objective: The aim of this study was to identify available evidence on the use of mobile apps to provide information and
facilitate communication regarding self-care management related to the adverse effects of toxicities owing to breast cancer
therapy.
Methods: This systematic review includes studies which were identified using a search strategy adapted for each electronic
database: CINAHL, Cochrane Library, LILACS, LIVIVO, PubMed, SCOPUS, and Web of Science. In addition, a gray literature
search was performed using Google Scholar. All the electronic database searches were conducted on April 17, 2019. Two
investigators independently reviewed the titles and abstracts of the studies identified and then read the full text of all selected
papers. The quality of the included studies was analyzed by the Cochrane Collaboration Risk of Bias Tool and the Methodological
Index for Non-Randomized Studies.
Results: A total of 9 studies which met the eligibility criteria—3 randomized clinical trials and 6 nonrandomized studies
published in English from 2010 to 2018—were considered for this systematic review; 396 patients with breast cancer, as well as
40 experts in the medical and nursing fields, and 3 software engineers were included.
Conclusions: The evidence from the studies included in this systematic review is currently limited but suggests that mobile
apps for women with breast cancer might be an acceptable information source that can improve patient well-being; they can also
be used to report symptoms and adverse treatment-related effects and promote self-care. There is a need to test more evidence-based
apps in future randomized clinical trials.
(JMIR Mhealth Uhealth 2019;7(8):e13245)  doi: 10.2196/13245
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Cancer is a major cause of morbidity, disability, and mortality
worldwide, affecting more than 18 million people each year
[1]. In Brazil alone, about 600,000 new cases of the disease are
estimated for 2019. Among women, the most common types of
cancer are those of the breast, intestines, cervix, lungs, and
thyroid. Worldwide, breast cancer is the most common cause
of death in women, with approximately 626,000 estimated
victims in 2018 [1,2].
The different modalities of cancer treatment can have adverse
effects that may reduce the quality of life of patients and lead
to treatment interruptions if not managed properly [3].
Considering the need to handle side effects in a population with
a life-threatening disease, promoting symptom
management–related knowledge remains a high priority for
patients and a challenge for health professionals [4-6].
The landscape of mobile app usage has been growing and
evolving. Apps can be used to offer services related to
entertainment, media, education, shopping, finances, travel,
health, and so on [7]. The use of mobile technologies presents
innovative possibilities for improving health care. Mobile apps
can help individuals manage their own health and well-being
and may also promote healthy lifestyles and information access.
According to international estimates, by 2018, nearly 2 billion
smartphone and tablet users were using health-related apps [8].
Considering the important role they can play in patient
education, disease self-management, and remote monitoring of
patients, the use of smartphones is receiving more attention in
the health domain every day. A systematic review investigating
smartphone-based health care technologies concluded that many
medical apps have been developed and are widely used by health
professionals and patients alike [9].
In a study evaluating 185 mobile apps related to breast disease
in the main app stores (Apple iTunes, Google Play, BlackBerry
World, and Windows Phone), the authors found that most
(n=139) concerned breast cancer [10]. A recent cross-sectional
review of 599 apps [11] has verified the state of the practice
regarding breast cancer-related mobile apps to characterize
health apps from app stores (iOS and Android). These studies
have identified a lack of evidence related to the involvement of
medical experts in the creation and development of such apps.
They have, therefore, highlighted the need to identify
high-quality apps to increase consumer confidence in their use
during health care [10,11].
A systematic review of apps targeting patients with breast and
prostate cancer involved 5 studies and a total of 644 patients.
The purposes of the apps were related to the main psychological
variables in psycho-oncological care: quality of life and anxiety
and depression symptoms [12]. Another systematic review
identified 29 studies on mobile health apps targeting only
patients with breast cancer. More than half of the studies
addressed apps in an intervention for prevention, early detection
of breast cancer, or survivors of the disease [13]. Both
systematic reviews found that rigorous trials regarding the
subject are lacking, despite the existence of studies related to
cancer-focused apps. Future investigations should continue to
explore and test the impact of mobile health apps on the
treatment of breast cancer [12,13].
None of these recent reviews exclusively evaluated apps for
women with breast cancer during cancer treatment. Therefore,
given the magnitude of the disease burden, the needs of this
population, the increasing use of mobile apps in the health
domain, and the need to identify quality apps, it is necessary to
enhance knowledge about the mobile apps available to provide
information and improve the course of treatment of women with
breast cancer.
Objective
This systematic review aimed to identify available evidence on
the use of mobile apps to provide information and facilitate
communication regarding self-care management related to the
adverse effects of toxicities owing to breast cancer therapy.
Methods
Protocol and Registration
This systematic review was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
Checklist [14]. The protocol was registered at the International
Prospective Register of Systematic Reviews under number
CRD42018083548 [15].
Eligibility Criteria
In this systematic review, we included the following: (1) studies
about mobile apps, defined as any computer programs or
software installed on mobile electronic devices to provide
information and facilitate communication regarding self-care
management and adverse effects related to toxicities owing to
breast cancer therapy, (2) studies that performed validation of
content or evaluated the usability or effectiveness of apps, and
(3) studies that collected the opinions of patients, clinicians, or
experts about apps developed for patients with breast cancer.
There were no restrictions on the year of publication or
language.
Studies were excluded for the following reasons: (1) if they
focused on mobile apps related to other types of cancer, (2) if
they focused on electronic technologies, but not mobile apps,
such as telephone services, text messages, videotapes,
audiotapes, audiovisual materials in DVDs, websites, games,
or online programs for desktop computers, (3) if they concerned
the post-treatment period, (4) if their objective was to evaluate
mobile apps intended for health professionals but not patients,
(5) if they focused on emotional, cognitive, and behavioral
strategies, and (6) if they took the form of reviews, letters,
conference summaries, book chapters, or studies that only
described the development of mobile apps.
Information Sources and Search Strategy
Studies were identified using an individual search strategy for
each of the following electronic databases: CINAHL, Cochrane
Library, LILACS, LIVIVO, PubMed, SCOPUS, and Web of
Science (Multimedia Appendix 1). The reference lists of selected
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papers were hand searched for potentially relevant studies that
might have been missed in the electronic database searches. In
addition, a gray literature search was performed using Google
Scholar.
Duplicated references were removed by using appropriate
software (EndNote Basic, Thomson Reuters). All the electronic
database searches were conducted on April 17, 2019.
Study Selection
Study selection was completed in 2 phases by using an online
app (Rayyan, Qatar Computing Research Institute). In phase 1,
2 investigators (FOAMC and PEDR) independently screened
the titles and abstracts of all citations retrieved from electronic
databases and identified papers that appeared to meet the
inclusion criteria. In phase 2, the same investigators
independently read the full text of all selected papers and
excluded studies that did not meet the inclusion criteria. Any
disagreements in the first or second phases were resolved by
discussion and consensus between the 2 reviewers. In case a
consensus could not be reached, a third investigator (EBF)
became involved to make a final decision. Studies that were
excluded after full-text assessment and the reasons for their
exclusion are listed in Multimedia Appendix 2.
Data Collection Process and Items
Two investigators (FOAMC and PEDR) independently collected
data from the selected papers: population characteristics (groups,
n, mean age, and treatment focus on app), study characteristics
(author(s), country and year of publication, and objective),
intervention characteristics (purpose of the app, operation,
description, and operating system), and outcome characteristics
(primary outcomes and main conclusions). Any disagreement
was resolved by discussion and mutual agreement. A third
author (EBF) was involved when required to make a final
decision. If the required data were not complete, attempts were
made to contact the authors to retrieve any pertinent information.
Risk of Bias in Individual Studies
Two investigators (FOAMC and PEDR) independently
conducted the risk of bias assessment for the selected papers.
Again, any disagreement was resolved by discussion and mutual
agreement. A third author (EBF) was involved when required
to make a final decision.
To assess the risk of bias of the included randomized controlled
trials, including judgments about sequence generation, allocation
concealment, blinding of participants, personnel and outcome
assessors, incomplete outcome data, and selective reporting,
the Cochrane Collaboration Risk of Bias Tool [16] was used.
The risk of bias was assessed as low, high, or unclear. We also
used the Methodological Index for Non-Randomized Studies
(MINORS) [17] for the nonrandomized studies; this was done
to analyze the study aim and appropriate endpoints, inclusion
of participants, data collection, and follow-up period, as well
as the calculation of the study size and loss to follow-up. For
the comparative study, the characteristics of the groups and the
statistical analyses were also verified.
Synthesis of Results
The heterogeneity across studies was evaluated by considering
clinical (treatment-related differences), methodological (design
and risk of bias), and statistical (outcome measures)
characteristics. Therefore, owing to the heterogeneity among
the included studies, a quantitative synthesis was not undertaken.
Congruent with the review objectives, the results of the included
studies were analyzed and reported according to the
characteristics of the mobile apps, their assessment, and
satisfaction with their use.
Results
Study Selection
The literature search initially yielded 3416 papers from 7
electronic databases. After duplicate removal, the titles and
abstracts of 2396 papers were screened, and 25 potentially
relevant studies were selected for full-text reading; 16 papers
were excluded (Multimedia Appendix 2) and 9 papers met all
the eligibility criteria and were considered for this systematic
review [18-26]. Figure 1 shows a flow diagram of the study
identification, screening, and inclusion processes.
Study Characteristics
All studies were published in English from 2010 to 2018 and
evaluated mobile apps for women with breast cancer during
treatment. In total, 4 studies included patients undergoing
chemotherapy [18-21], 1 concerned postoperative patients [22],
and another focused on both chemotherapy and surgery [23].
One study included patients undergoing chemotherapy and
radiation therapy [24], and another included patients undergoing
adjuvant endocrine therapy with aromatase inhibitors [25]. Only
one study allowed any type of therapy for breast cancer [26].
In this systematic review, 396 patients with breast cancer were
included, as well as 40 medical and nursing experts and 3
software engineers. The clinical nursing experts’ average career
length was 17.0 years, with the duration ranging from 7 to 36
years in one of the studies [23]. One study included 2 breast
surgeons, an oncologist, a radiation oncologist, a plastic surgeon,
a gynecologist, a clinical geneticist, and 3 specialized breast
cancer nurses [26].
A study measured health literacy through a validated instrument,
showing that 72.5% of participants had high health literacy [25].
Regarding educational level, in 1 study, 56.1% of the
participants had completed elementary or junior middle school
[21]. Concerning familiarity with mobile apps, 1 study found
that 67% of the participants frequently used them, while 33%
were relatively inexperienced before participating in the study
[26].
The main characteristics of the studies included are presented
in Tables 1, 2, and 3.
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Figure 1. Flow diagram of literature search and selection process (adapted from Preferred Reporting Items for Systematic Reviews and Meta-Analyses
[PRISMA]).
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Table 1. Summary of population characteristics of included papers (n=9).
App’s treatment focusMean age (years)NGroupsYear, author, countrya
ChemotherapyCG: 56; EG1: 50; EG2: 53CG: 41 patients; EG1: 45
patients; EG2: 41 patients
CGb: regular physician sup-
port; EG1c: mobile app
without physician review;
EG2: mobile app and physi-
cian review on scheduled
visits




CG: 59.3; EG: 60.6CG: 23 patients; EG: 21 pa-
tients
CG: mobile app without
weekly reminders to use it;
EG: mobile app with weekly
reminders to use it
2018, Graetz et al, United
States [25]
SurgeryCG: 65.5; EG: 60.1CG: 37 patients; EG: 35 pa-
tients
CG: conventional follow-up;
EG: e-monitoring in addi-
tion to conventional follow-
up
2016, Hwang, Canada [22]
Chemotherapy (n=3) and
radiation therapy (n=2)
505 patientsTwo groups of patients
evaluated the app for three
weeks
2010, Klasnja et al, United
States [24]
Surgery and chemotherapyEvG1: 38.9; EvG2: not
available
EvG1: 19 nurses; EvG2: 8
experts
EvG1d: clinical nursing ex-
perts; EvG2: medical and
nursing experts and software
engineers
2017, Liu et al, China [23]
Any type of cancer therapyEvG1: 51; EvG2: not avail-
able
EvG1: 15 patients; EvG2:
10 experts
EvG1: patients with breast
cancer; EvG2: physicians
and specialized nurses
2016, Young-Afat et al, The
Netherlands [26]
ChemotherapyEvG1: not available; EvG2:
above 50
EvG1: 6 experts; EvG2: 6
patients
EvG1: specialized nurses
and an oncologist; EvG2:
patients with breast cancer
2017, Zhu et al, China [19]
Chemotherapy49.513 patientsTwo groups (FTFIe and TIf)
of patients that evaluated the
app
2018, Zhu et al, China [20]
ChemotherapyA: 46.2; B: 48.2A: 57 patients; B: 57 pa-
tients
CG: only usual care; EG: e-
support program and usual
care
2018, Zhu et al, China [21]
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Table 2. Summaries and intervention characteristics of included papers (n=9).
Intervention characteristicsStudy characteristicsYear, author, countrya
OperationPurpose of the appObjective
The app allows patients to record
their daily functional activity and
Improvement in the patient-reported
functional activity and adverse ef-
fects of chemotherapy
To evaluate the effects of a mobile
app on patient-reported daily func-
tional activity
2016, Egbring et al, Switzerland
[18]
perceived symptoms during
chemotherapy with indications of
severity. Patients can edit a list of
their preselected symptoms or select
any of the 48 symptoms available.
The ability to report symptoms and
AI medication use, with built-in
Improvement in symptom burden
and medication adherence
To evaluate the feasibility of a Web-
based symptom-reporting app for
patients with early-stage breast can-
cer using AIsb
2018, Graetz et al, United States
[25]
alerts sent to a patient’s care team
on the basis of the predetermined
thresholds.
The app allows for electronic wound
monitoring. The patient takes photos
Provision of care for postoperative
wounds
To determine if unscheduled visits
for care and hospital readmission
can be prevented by e-monitoring
2016, Hwang, Canada [22]
of the wound on postoperative days
and to assess patient satisfaction
with the app
1, 3, 7, and 14 and attaches them to
electronic messages sent to the sur-
geon, who must answer within 24
hours.
The app has modules including daily
check-ins to track well-being and
Provision of health information to
manage care-related issues in unan-
chored settings
To refine the functional require-
ments of a mobile app to assist pa-
tients with cancer during treatment
2010, Klasnja et al, United States
[24]
symptoms; calendar events (eg,
consultations with clinicians); logs
to monitor medications, pain, and
surgery drains; and notes (ie, text,
photo, and audio) for quick capture
of care-related information.
The app has 5 main function mod-
ules: personalized information rec-
Provision of information support
regarding disease, treatment, medi-
To develop and evaluate the struc-
ture and contents of a smartphone
app for women with breast cancer
2017, Liu et al, China [23]
ommendation, category knowledge
center, headline information brows-
cation, exercise, nutrition, symp-
toms, examination, and social sup-
port ing, newest information browsing,
and information searching.
The app has 4 main functionalities:
repository for information (audio
To be beneficial in clinical practice
and research
To evaluate patient experience and
satisfaction, physicians’ and nurses’
opinions, and scientific potential of
a supportive breast cancer app
2016, Young-Afat et al, The
Netherlands [26]
recorded and imaging), symptom
registration, timeline of treatment
trajectory, and personalized informa-
tion about breast cancer and treat-
ment.
The app has 4 components: learning
(information related to breast cancer
Provision of social, emotional, and
information support
To develop and evaluate the content
and functionality of a mobile app
for women with breast cancer under-
going chemotherapy
2017, Zhu et al, China [19]
and symptom management), discus-
sion (anonymous support group),
ask the expert (online consultation),
and personal stories (stories of
breast cancer survivors).
The app has 4 components: learning
(information related to breast cancer
Provision of social, emotional, and
information support
To explore participants’ perceptions
of the strengths and weaknesses of
the BCSc, and their suggestions for
program improvement
2018 A, Zhu et al, China [20]
and symptom management), discus-
sion (anonymous support group),
ask the expert (online consultation),
and personal stories (stories of
breast cancer survivors).
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Intervention characteristicsStudy characteristicsYear, author, countrya
OperationPurpose of the appObjective
The app has 4 components: learning
(information related to breast cancer
and symptom management), discus-
sion (anonymous support group),
ask-the expert (online consultation),
and personal stories (stories of
breast cancer survivors).
Provision of social, emotional, and
information support
To determine the effectiveness of
the BCS program to address wom-
en’s self efficacy, symptoms, and
quality of life during chemotherapy
2018 B, Zhu et al, China [21]
aCountry of the study coordinator.
bAIs: aromatase inhibitors.
cBCS: Breast Cancer e-Support Program.
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Table 3. Summary of interventions and outcome characteristics of included papers (n=9).
Outcome characteristicsIntervention characteristicsYear, author, countrya
Main conclusionsPrimary outcomesOperating systemDescription (developer)
Patient well-being and re-
porting of the adverse ef-
Functional activity and ad-
verse effects of chemothera-
py
iOSb and AndroidMobile app to record daily
functional activity and ad-
verse effects of chemothera-
py
2016, Egbring et al,
Switzerland [18]
fects of chemotherapy can
be improved by using a mo-
bile app under the supervi-
sion of the treating physi-
cian.
The use of an app with
weekly reminders significant-
Symptom burden and medi-
cation adherence
Information not availableApp that allows patients to
share information in real
time with their cancer care
team outside of clinic visits
2018, Graetz et al, United
States [25]
ly improved short-term AIc
adherence, which may re-
duce the symptom burden of
women with breast cancer.
Electronic wound monitor-
ing was associated with sig-
Unscheduled visits for care,
hospital readmission, and
patient satisfaction
Information not availableSmartphone app that allows
for communication between
the patient and the surgeon
(Medeo)
2016, Hwang, Canada [22]
nificantly less unscheduled
care, including hospital
readmission and visits to the
emergency department or
walk-in clinic, a high degree
of patient satisfaction, and a
possible reduction in cost to
the health care system.
The possibility of taking
photos and audio notes was
Participants’ perceptions of
HealthWeaver Mobile
Android onlyMobile app to assist patients
in managing care-related in-
formation (HealthWeaver
Mobile)
2010, Klasnja et al, United
States [24]
highly valued by partici-
pants. The app was seen not
only as a valuable way to
capture information quickly
but also as a means of access-
ing information, especially
through calendar events.
A few useful pieces of infor-
mation, photos, and videos
Participants’ evaluation of
Information Assistant




2017, Liu et al, China [23]
have been added, allowing
patients to gain maximum
benefits from the app. It is
able to deliver high-quality
information support.
Benefits for patients and
their medical teams, especial-
Participants’ evaluation of
OWise
iOS and AndroidSupportive breast cancer
mobile app to assist in clini-
cal practice and research
(OWise)
2016, Young-Afat et al, The
Netherlands [26]
ly because of the option to
make audio recordings of
consultations and the avail-
ability of personalized infor-
mation.
More information has been
added in the app tutorial, as
Participants’ evaluation of
BCS
iOS and AndroidMobile app to promote
women’s self-efficacy and
social support (BCSd)
2017, Zhu et al, China [19]
well as the information relat-
ed to food choices, sexual
activity, pregnancy, and the
interpretation of laboratory
results, making the app use-
ful, attractive, and easy to
use.




iOS and AndroidMobile app to promote
women’s self-efficacy and
social support (BCS)
2018, Zhu et al, China [20]
py. Its benefits can be maxi-
mized by incorporation into
routine care.
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Outcome characteristicsIntervention characteristicsYear, author, countrya
Main conclusionsPrimary outcomesOperating systemDescription (developer)
The BCS program demon-
strated its potential as an ef-




quality of life during
chemotherapy.
Self-efficacyiOS and AndroidMobile app to promote
women’s self-efficacy and
social support (BCS)
2018, Zhu et al, China [21]
aCountry of the study coordinator.
biOS: iPhone Operating System.
cAIs: Aromatase Inhibitors.
dBCS: Breast Cancer e-Support Program.
Risk of Bias Within Studies
On the basis of the methodological quality assessment using
MINORS [17], the total scores of the validation studies ranged
from 12 to 16 [19,20,23,24,26], while the nonrandomized
comparative study reached a total score of 21 [22], as shown in
Table 4.
On the basis of the methodological quality assessment using
the Cochrane Collaboration Risk of Bias Tool [16], one of the
studies [21] presented a low risk of bias in all domains
evaluated. Only one of the studies [18] presented high risk in
2 domains, both regarding blinding; the authors indicated that
the absence of blinding may have affected the outcomes
evaluated. In one study, there were no reports regarding blinding
of outcome assessment [26], as shown in Figure 2.
Table 4. Methodological appraisal of selected studies on the basis of Methodological Index for Nonrandomized Studies (MINORS).
Zhu et al 2018
[20]











2222221. A clearly stated aim
0222222. Inclusion of consecutive patients
2222223. Prospective collection of data
2222224. Endpoints appropriate to aim of study
2222225. Unbiased assessment of study end-
point
2022226. Follow-up period appropriate for aim
of study
2202027. Loss to follow-up less than 5%
2222018. Prospective calculation of study size
N/AN/AN/AN/AN/Ab29. An adequate control group
N/AN/AN/AN/AN/A110. Contemporary groups
N/AN/AN/AN/AN/A111. Baseline equivalence of groups
N/AN/AN/AN/AN/A212. Adequate statistical analyses
141414161221Total score
aItems were scored 0 (not reported), 1 (reported but inadequate), or 2 (reported and adequate). The global ideal total score is 16 for noncomparative
studies and 24 for comparative studies. See list of references for full source information on papers. MINORS index is described in Slim et al [14].
aNot applicable.
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Figure 2. Methodological appraisal of selected studies on the basis of Cochrane Collaboration Risk of Bias Tool.
Synthesis of Results
All the analyzed studies carried out the evaluation of mobile
apps for women during the treatment of breast cancer. On the
basis of the objective, different types of apps were developed.
In general, all involved the provision of useful and quality
information to patients as a way of improving management of
adverse treatment effects through the promotion of self-care at
home.
Some studies reported the importance of using the specific app
under the supervision of health professionals, either online
[19,22,25] or in person [18]. Two studies evaluated an app
capable of communicating with health care professionals,
providing remote electronic monitoring [22,25]. One study
developed a pilot randomized controlled trial to assess the
feasibility of an app with or without weekly reminders, allowing
the sharing of health information on a real-time basis with the
patient’s oncology care team. Participants who used the weekly
reminders feature had a higher app usage rate (74% vs 38%,
P<.05) during the intervention and reported higher drug
adherence than those who did not opt for this feature (100% vs
72%, P<.05) [25].
Another study reported a significantly lower number of
unexpected medical consultations, including hospital
readmissions and visits to the emergency department, in the
e-monitoring group than the conventional follow-up control
group (3% vs 22%, P<.05), as the app allows the professional
to conduct an electronic consultation if necessary, avoiding
complications. Almost all e-monitoring patients felt that the
app led to improved care (95%) and would recommend it to a
friend or colleague (90%).
Three studies in this systematic review [19-21] concerned an
app with an ask the expert module, capable of providing online
consultations, which was found to be useful, attractive, and easy
to use [19]. The authors developed and evaluated the content
and functionality of the mobile app [19], tested it to determine
its effectiveness regarding women’s self efficacy, symptoms,
and quality of life during chemotherapy [21], and explored
participants’ perceptions of app strengths and weaknesses [20].
Through qualitative interviews, it emerged that the participants
considered the app to be useful for improving knowledge and
promoting emotional well-being and would recommend it to
other women undergoing chemotherapy [20]. In addition, when
tested, the app had significantly better health outcomes at 3
months regarding self-efficacy (21.05; 95% CI 1.87 to 40.22;
P=.03; d=0.53), symptom interference (−0.73; 95% CI −1.35
to −0.11; P=.02; d=−0.51), and quality of life (6.64; 95% CI
0.77 to 12.50; P=.03, d=0.46) compared with participants who
received usual care [21].
Another study reported the importance of an app for patients
who require face-to-face follow-up with health care
professionals on scheduled visits. Through the app, the patient
can make a recording of the perceived symptoms at home,
improving the report of the adverse effects management for the
health care professional during consultation [18].
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The focus of some studies was on using mobile apps to improve
the retention of information about the management of adverse
effects and, consequently, to improve self-care and patient
well-being. One study evaluated an app with a module dedicated
to the latest research findings, technologies, and methods for
breast cancer care, thereby helping patients obtain up-to-date
information [23].
Moreover, one study assessed a mobile app that, in addition to
offering patient guidance through the provision of knowledge,
includes a calendar to highlight important dates related to events,
treatments, and consultations. This app incorporates texts,
photos, and audio, making it possible for patients to capture and
store important information related to their care. This app allows
greater interaction between the patient and the app, a fact that
was valued by the study participants [24].
However, this was not the only study on an app enabling the
inclusion of audio. In another study, all patients (n=15) used
the audio recording function to record consultations with their
nurses and physicians, and 14 (93%) patients found this feature
useful. Patients considered the audio aspect and the
personalization of information about disease and treatment as
the most useful features of the app. Almost all physicians and
nurses (90%) also found the recording function useful and would
recommend the app to their patients [26]. Figure 3 shows
screenshots of this smartphone app, named OWise.
Figure 3. Screenshots of the OWise.
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This is a systematic review about the available evidence
regarding women’s use of mobile apps during breast cancer
treatment. A total of 9 papers, which covered the development
of various types of mobile apps, were included [18-26]. The
apps encompassed the transmission of useful information and
the management of the adverse effects of breast cancer treatment
through various features.
While there is growing interest in using patient reporting tools
to improve symptom monitoring during cancer treatment, there
is a lack of evidence about the impact of this strategy on clinical
outcomes [26,27]. A mobile app has the potential to restore the
daily functional activity of patients with early-stage breast
cancer. This benefit is most significant when the patient uses
the app under the supervision of health professionals as the
review of the treatment during consultation is an opportune
moment for a sincere discussion of symptoms reported by the
patients in the app [18].
Electronic follow-up via apps may help avoid unplanned visits
to the emergency room and hospital readmissions, reducing
health care costs [22]. These results corroborate those of a study
that examined health-related quality of life, emergency room
visits, and hospitalizations among patients receiving
chemotherapy for advanced solid tumors. The use of tablet
computers to self-report symptoms during cancer treatment was
associated with significant clinical benefits, decreased
emergency room admissions, and reduced hospitalizations [27].
Web-based self-management support systems and apps
involving health professionals are important to ensure the
communication of high-quality information between patients
and the health team empowering the patients to increase their
self-care and improve their own health [28] and also the
communication between patients and staff outside of health
institutions as a way of ensuring continuity of care [22],
enhancing knowledge, improving confidence level, and
promoting emotional well-being [20]. Besides that, the
involvement of health professionals in monitoring treatment
effects through an app outside of clinic visits also might be a
cost-effective way to improve symptom management and health
outcomes [25].
Calendar events, photos, messages, and audio are a few of the
mechanisms that can increase the usability of apps and improve
the acquisition of information related to illness and treatment
[18,24,26]. These features may improve self-care at home and
restore the daily functional activity of patients. In addition, the
audio recording function to record consultations with health
professionals does not increase the duration of the consultation
[26].
Characteristics related to communication and interaction were
also demonstrated by a recent study that aimed to investigate
the behavior of patients with prostate cancer when using a
mobile app during radiation therapy [29]. As found in the studies
included in this systematic review, there was improvement in
the reporting and self-management of symptoms during
treatment. In addition, the app provided continuous access to
links to important information and, like one of the apps
evaluated by a study included in this review, helped patients
obtain up-to-date information regarding their disease and
treatment [23].
In this context, health apps are increasingly being used in clinical
care and might have significant informative potential. However,
they are often inserted into clinical care before the necessary
research to confirm the benefits for patients and health
professionals has been conducted [26].
Limitations
Some methodological limitations of this systematic review
should be taken into account. Most studies validated apps for
mobile devices during their development, focusing on their
content and functionality. More data from randomized clinical
trials are needed to assess the effects of using mobile apps during
the treatment of women with breast cancer, as is being done
with the Breast Cancer e-Support program. In addition, the
evaluated apps have different functionalities and are geared
toward different treatments. Therefore, their heterogeneity
prevents the data from being satisfactorily grouped, hindering
a quantitative analysis.
Conclusions
The evidence from the studies included in this systematic review
is currently limited but suggests that mobile apps for women
with breast cancer might be an acceptable information source
and lead to improved patient well-being. They can also be used
to report symptoms and adverse treatment-related effects and
promote self-care. However, the real utility of mobile apps for
women undergoing breast cancer treatment is still uncertain.
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